Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Entera Bio Ltd. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 14 | 18 | +4 |
| Shares | 7.49M | 10.2M | +2.73M (+36.4%) |
| Value | $15.9M | $17.4M | +$1.48M (+9.3%) |
New holders (4)
Institutions that held Entera Bio Ltd. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 2,697,236 | $4.59M | 0.01% |
| Two Sigma Securities, LLC | 12,554 | $21.3K | 0.00% |
| XTX Topco Ltd | 10,859 | $18.5K | 0.00% |
| Cubist Systematic Strategies, LLC | 1,560 | $2.65K | 0.00% |
Sold out (0)
Institutions that held Entera Bio Ltd. at the end of Q4 2024 and filed for Q1 2025 without it.
None.